PDF下载

[1]洪立信杨毅夏宇贾宇衡田侃王志刚张芃何露洋.基于离散选择实验的结直肠癌患者药物治疗偏好的属性与水平开发研究[J].中国卫生质量管理,2026,33(6):73-78.[doi:10.13912/j.cnki.chqm.2026.33.6.16]
　HONG Lixin,YANG Yi,XIA Yu.Research on the Development of Attributes and Levels for Medication Treatment Preferences in Colorectal Cancer Patients Based on Discrete Choice Experiment[J].Chinese Health Quality Management,2026,33(6):73-78.[doi:10.13912/j.cnki.chqm.2026.33.6.16]

点击复制

基于离散选择实验的结直肠癌患者药物治疗偏好的属性与水平开发研究

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R] 卷: 33 期数: 2026年6期页码: 73-78 栏目: 卫生技术评估专栏出版日期: 2026-06-15

Title:: Research on the Development of Attributes and Levels for Medication Treatment Preferences in Colorectal Cancer Patients Based on Discrete Choice Experiment

作者:: 洪立信杨毅夏宇贾宇衡田侃王志刚张芃何露洋; 上海应用技术大学人文学院

Author(s):: HONG Lixin; YANG Yi; XIA Yu; School of Pharmacy, Nanjing University of Chinese Medicine

关键词:: 离散选择实验; 结直肠癌; 用药治疗偏好; 用药属性; 用药水平

Keywords:: Discrete Choice Experiment; Colorectal Cancer; Medication Treatment Preference; Medication Attribute; Medication Level

分类号:: R197；R735.3

DOI:: 10.13912/j.cnki.chqm.2026.33.6.16

文献标志码:: A

摘要:: 目的通过对结直肠癌治疗偏好属性的遴选和水平的确立，以期指导结直肠癌临床用药，为国内离散选择实验（DCE）研究提供借鉴。方法系统检索结直肠癌治疗偏好相关文献，初步拟定属性及水平；通过对6名医师和12例患者进行访谈，明确属性及水平；最后形成问卷，开展预实验，检验DCE属性及水平设置合理性。结果共纳入10篇相关文献，通过梳理选取12个属性及其对应的水平。在医师咨询及患者访谈后，保留6个重要属性，分别为无进展生存期、生命质量、进食和消化的影响、严重治疗副作用（＞3级）发生率、给药频率、每月自付费用。进行预实验后，发现属性及水平设置合理，问卷填写负担适中。结论本研究开发了结直肠癌患者用药治疗选择偏好的属性及水平，可为国内DCE研究属性及水平开发工作提供借鉴，指导结直肠癌临床合理用药。

Abstract:: ObjectiveTo guide clinical medication for colorectal cancer by selecting preference attributes and establishing their levels, providing a reference for the domestic discrete choice experiment (DCE) research. MethodsA systematic literature search was conducted on treatment preferences for colorectal cancer to initially identify relevant attributes and levels. Interviews were then carried out with 6 physicians and 12 patients to refine these attributes and levels. Subsequently, a questionnaire was developed, and a pilot study was conducted to test the rationality of the DCE attributes and levels. ResultsA total of 10 relevant studies were included, from which 12 attributes and their corresponding levels were initially selected. After consulting physicians and interviewing patients, 6 important attributes were retained: progression-free survival, quality of life, impact on eating and digestion, incidence of severe treatment-related side effects (grade >3), frequency of drug administration, and monthly out-of-pocket expenses. The pilot study confirmed that the attributes and levels were reasonably set, and the questionnaire imposed a moderate burden on respondents.Conclusion This study developed attributes and levels for medication treatment preferences among colorectal cancer patients, offering a reference for the development of attributes and levels in domestic DCE research and guiding rational clinical medication for colorectal cancer.

参考文献/References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2024,74(3):229-263.［2］中华医学会肿瘤学分会，国家卫生健康委员会医政司. 中国结直肠癌诊疗规范(2023版)［J］. 协和医学杂志, 2023,14(4):706-733.［3］MOREAU BC, COQUAN E, DU RUSQUEC P, et al. Risks and benefits of anticancer drugs in advanced cancer patients: a systematic review and meta-analysis［J］. E Clinical Medicine, 2021,40:101130.［4］孙浩，刘尧，王家林，等. 癌症患者参与医患共同决策行为意愿动力机制研究——基于计划行为理论模型和结构方程模型［J］. 中华肿瘤防治杂志, 2023,30(20):1236-1241.［5］许越，李雨畅，陈星宇，等. 基于优劣尺度法的老年人居家照护服务选择偏好及支付意愿分析［J］.中国卫生质量管理,2024,31(8):23-29.［6］LANCSAR E, LOUVIERE J.Conducting discrete choice experiments to inform healthcare decision making: a user’s guide［J］.Pharmacoeconomics,2008,26(8):661-677.［7］BRIDGES JF, HAUBER AB, MARSHALL D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force［J］. Value Health, 2011,14(4):403-413.［8］吕玉玉，李顺平，路立勇，等. 基于离散选择实验的试管婴儿治疗偏好属性及水平开发研究［J］. 医学与社会, 2024,37(7):86-93.［9］王秋臣，张秀英，薛辉，等. 开发离散选择实验属性和水平的研究进展［J］. 现代预防医学, 2020,47(12):2199-2201.［10］OBADHA M,BARASA E,KAZUNGU J,et al.Attribute development and level selection for a discrete choice experiment to elicit the preferences of health care providers for capitation payment mechanism in Kenya［J］. Health Econ Rev, 2019,9(1):30.［11］FENG Z, MENG J, SUN Y, et al. Assessment of patients’ preferences for new anticancer drugs in China: a best-worst discrete choice experiment on three common cancer types［J］. BMJ Open, 2023,13(6):e72469.［12］HEINEMANN V, SINGH M, HARDTSTOCK F, et al.Assessment of metastatic colorectal cancer patients’ preferences for biologic treatments in germany using a discrete choice experiment［J］. Clin Colorectal Cancer, 2022,21(2):122-131.［13］WONG XY, LIM A, SHEN Q, et al. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment［J］. Curr Med Res Opin, 2020,36(10):1677-1686.［14］SCHMIDT K, DAMM K, VOGEL A, et al.Therapy preferences of patients with lung and colon cancer: a discrete choice experiment［J］. Patient Prefer Adherence, 2017,11:1647-1656.［15］GONZALEZ JM,OGALE S,MORLOCK R,et al.Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment［J］. Cancer Manag Res, 2017,9:149-158.［16］BRIDGES JF, LA CRUZ M, PAVILACK M, et al.Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer［J］. Future Oncol, 2019,15(34):3895-3907.［17］孙辉，陈英耀，任绍聪，等. 非小细胞肺癌患者疾病治疗偏好与意愿支付研究［J］. 卫生经济研究, 2018(9):6-9.［18］STAMULI E, CORRY S, ROSS D, et al. Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain［J］. Future Oncol, 2022,18(9):1115-1132.［19］WEILANDT J, DIEHL K, SCHAARSCHMIDT ML, et al.Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment［J］. Acta Derm Venereol, 2020,100(6):adv83.［20］FIFER SJ, HO KA, LYBRAND S, et al. Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences［J］. BMC Cancer, 2020,20(1):546.［21］VERSTEEG AL, SAHGAL A, KAWAHARA N, et al. Patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases［J］. Cancer, 2019,125(23):4269-4277.［22］孙康宁，张秀杰，王春辉，等. 山东省中晚期结直肠癌患者生命质量现状及影响因素分析［J］. 中华肿瘤防治杂志, 2023,30(15):897-903.［23］BRUNDAGE MD, DAVIDSON JR, MACKILLOP WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer［J］. J Clin Oncol, 1997,15(1):330-340.［24］ANDRE T,FALCONE A,SHPARYK Y,et al.Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study［J］. Lancet Gastroenterol, 2023,8(2):133-144.［25］滕悦,魏艳,陈英耀,等.中药注射剂抗肿瘤治疗的医患偏好及共同决策比较分析［J］.中国卫生质量管理,2023,30(2):60-64，69.［26］邓明,林伟龙,时黎明,等.北京市79家医院抗肿瘤药物规范使用现状与影响因素分析［J］.中国卫生质量管理,2022,29(11):21-24，29.［27］祝琦,黄慧瑶,房虹,等.基于离散选择实验的肿瘤治疗偏好研究［J］.医学与社会,2022,35(5):123-129.［28］周琴,李海麟,谷玉婷,等.广州市结直肠癌及癌前病变患者疾病经济负担及影响因素分析［J］.中国肿瘤,2020,29(1):7-13.［29］国家药品监督管理局药品审评中心.关于公开征求ICH《E22：患者偏好研究的一般考虑》指导原则草案意见的通知［EB/OL］.(2026-01-23)［2026-01-24］.https://www.cde.org.cn/main/news/viewInfoCommon/9a9c3213a4f44e502bf7b18bbe93 333d.

相似文献/References:

[1]庄英朱晓萍陈亚梅尹小兵胡龙军钱明平余松轩侯冷晨张戟.基于加速康复外科的结直肠肿瘤中心化建设[J].中国卫生质量管理,2021,28(12):8.[doi:10.13912/j.cnki.chqm.2021.28.12.03 ]
　ZHUANG Ying,ZHU Xiaoping,CHEN Yamei.Construction of Colorectal Tumor Center Based on Enhanced Recovery After Surgery[J].Chinese Health Quality Management,2021,28(6):8.[doi:10.13912/j.cnki.chqm.2021.28.12.03 ]
[2]郑吕云曾令黄刘志刚曹晨晨刘静.基于离散选择实验的医务人员激励偏好研究[J].中国卫生质量管理,2024,31(04):59.[doi:10.13912/j.cnki.chqm.2024.31.4.12]
　ZHENG Lvyun,ZENG Linghuang,LIU Zhigang,et al.Incentive Preference of Medical Staff Based on Discrete Choice Experiment[J].Chinese Health Quality Management,2024,31(6):59.[doi:10.13912/j.cnki.chqm.2024.31.4.12]

更新日期/Last Update: 2026-06-15